| Literature DB >> 32171329 |
Gustavo Gomes Resende1, Eduardo de Souza Meirelles2, Cláudia Diniz Lopes Marques3, Adriano Chiereghin4, Andre Marun Lyrio5, Antônio Carlos Ximenes6, Carla Gonçalves Saad2, Célio Roberto Gonçalves2, Charles Lubianca Kohem7, Cláudia Goldenstein Schainberg2, Cristiano Barbosa Campanholo8, Júlio Silvio de Sousa Bueno Filho9, Lenise Brandao Pieruccetti10, Mauro Waldemar Keiserman11, Michel Alexandre Yazbek12, Penelope Esther Palominos7, Rafaela Silva Guimarães Goncalves3, Ricardo da Cruz Lage13, Rodrigo Luppino Assad14, Rubens Bonfiglioli5, Sônia Maria Alvarenga Anti15, Sueli Carneiro16, Thauana Luíza Oliveira17, Valderílio Feijó Azevedo18, Washington Alves Bianchi19, Wanderley Marques Bernardo20, Marcelo de Medeiros Pinheiro17, Percival Degrava Sampaio-Barros20.
Abstract
Spondyloarthritis is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. The classification axial spondyloarthritis is adopted when the spine and/or the sacroiliac joints are predominantly involved. This version of recommendations replaces the previous guidelines published in May 2013.A systematic literature review was performed, and two hundred thirty-seven studies were selected and used to formulate 29 recommendations answering 15 clinical questions, which were divided into four sections: diagnosis, non-pharmacological therapy, conventional drug therapy and biological therapy. For each recommendation the level of evidence supporting (highest available), the strength grade according to Oxford, and the degree of expert agreement (inter-rater reliability) is informed.These guidelines bring evidence-based information on clinical management of axial SpA patients, including, diagnosis, treatment, and prognosis.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32171329 DOI： 10.1186/s42358-020-0116-2
Source DB: PubMed Journal: Adv Rheumatol ISSN： 2523-3106